STAT+: Pharmalittle: We’re reading about U.S. pressuring Germany on drug prices, FDA upheaval and biotech clinical trials, and more
As the workweek ends, there's excitement for weekend plans involving music and outdoor activities, while also encouraging safe enjoyment of leisure time. In a separate context, U.S. officials are urging Germany to increase pharmaceutical payments, and some U.S. biotech firms are contemplating relocating early-stage trials abroad due to concerns over regulatory delays under the Trump administration.
The most valuable insight for someone in your field is the growing trend of U.S. biotech companies considering moving early-stage trials abroad due to concerns about FDA upheaval under the Trump administration. This shift could signal potential opportunities for collaboration and investment in international markets, such as the EU and Australia, as these regions may become increasingly pivotal in the drug development process.